Viking Therapeutics, Inc. (NASDAQ:VKTX) – Zacks Investment Research lowered their Q3 2017 EPS estimates for shares of Viking Therapeutics in a report issued on Monday. Zacks Investment Research analyst D. Bautz now anticipates that the biotechnology company will post earnings per share of ($0.19) for the quarter, down from their previous forecast of ($0.16). Zacks Investment Research also issued estimates for Viking Therapeutics’ Q4 2017 earnings at ($0.19) EPS, FY2017 earnings at ($0.81) EPS, FY2018 earnings at ($0.72) EPS and FY2019 earnings at ($0.70) EPS.
VKTX has been the subject of several other research reports. ValuEngine cut shares of Viking Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th. HC Wainwright reissued a “buy” rating and set a $7.00 target price (up previously from $5.00) on shares of Viking Therapeutics in a report on Monday, July 17th. Finally, Maxim Group reissued a “buy” rating and set a $5.00 target price on shares of Viking Therapeutics in a report on Thursday, May 11th.
Shares of Viking Therapeutics (VKTX) opened at 1.00 on Thursday. The company’s market cap is $27.70 million. Viking Therapeutics has a 12 month low of $0.88 and a 12 month high of $1.70. The stock’s 50 day moving average is $1.06 and its 200-day moving average is $1.26.
Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.02.
A hedge fund recently raised its stake in Viking Therapeutics stock. Renaissance Technologies LLC boosted its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 666.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 163,200 shares of the biotechnology company’s stock after buying an additional 141,900 shares during the period. Renaissance Technologies LLC owned 0.81% of Viking Therapeutics worth $194,000 as of its most recent SEC filing. Institutional investors own 2.79% of the company’s stock.
About Viking Therapeutics
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
What are top analysts saying about Viking Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Viking Therapeutics Inc. and related companies.